The EPS projection of Laboratory Corporation of America Holdings (NYSE:LH) for quarter ended 2016-09-30 is $2.29. Last week, the projection for EPS was $2.29 against target of $2.29, a month earlier. While 2-months ago, this projection was $2.29 versus forecast of $2.29a quarter months earlier, posting a deviation of 0%.
Laboratory Corporation of America Holdings (NYSE:LH) posted that 18 days earlier, the share price was revised 3 times on upside. In addition, negative revisions were 5.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 1 and 2. While in last 120 and 90 days, positive revisions were 8, and 7, correspondingly.
The per-share earnings downgrade for Laboratory Corporation of America Holdings (NYSE:LH) in the preceding 30 and 120 were 0 and 2. While in 60 and 90 days were 0, and 3, in that order.
Laboratory Corporation of America Holdings (NYSE:LH) EPS target was $2.29 for the quarter closed 1. It was based on 11 calls. As on 2016-04-25 the EPS was $2.02. The change was $0.06, posting a deviation of 3.06%. The price projections gave a standard deviation of 0.04.
Quarterly Sales Estimates
Laboratory Corporation of America Holdings (NYSE:LH) sales prediction for the fiscal 2017 stands at $2454 and the median estimate is at $2454.9. Almost 3 analysts gave sales target.
Among this, the highest sales estimate is $2459.6 while the lowest target is $2447.5 showing standard deviation of 6.1%.
As many as 3 analysts have positive sales targets revision while 3 reduced sales estimates, posting a deviation of 0%.
Last month, 3 experts have positive sales number revision. Also, 3 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast, posting a deviation of 0.705%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...